Showing results (581-590 of 669) with videos related to

Sort By:
Pageof 67
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Hemasphere|January 18, 2021
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and TreatmentJaap A van Doesum, Anne G H Niezink, Gerwin A Huls, et al.
Hemasphere|April 6, 2026
Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemiaMarta Santaliestra, Marta Garrote, María Concepción Fernández-Rodríguez, et al.
Hemasphere|June 5, 2023
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study ProtocolCarmelo Rizzari, Anja Möricke, Maria Grazia Valsecchi, et al.
Hemasphere|June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic LeukemiaChiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Hemasphere|June 8, 2026
Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis-endemic settingKatherine Antel, Nina Xiong, Mwanasha Merrill, et al.
Hemasphere|June 9, 2026
Lamin B1 safeguards the B cell genome and shapes lymphoma outcomeFilip Filipsky, Katarina B Chapman, Johannes Bloehdorn, et al.
Hemasphere|April 6, 2026
Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformationSuzana da Silva-Benedito, Paula Sabbo Bernardo, Jean-Edouard Martin, et al.
Hemasphere|April 6, 2026
Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myelomaThomas C Wiemers, Michael Rade, Nora Grieb, et al.
Hemasphere|April 20, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 studyStefano Luminari, Ana Jiménez-Ubieto, Geoffrey Chong, et al.
Pageof 67